Clinical trials: Proton Pump Inhibitors
Laryngomalacia
Assessing the Role of Proton Pump Inhibitors in Reducing Aspiration Incidence in Pediatric Laryngomalacia Cases
Laryngomalacia is the most common congenital laryngeal anomaly in children and is frequently associated with aspiration. This randomized controlled study aims to assess the role of proton pump inhibitor (PPI) therapy in reducing…
- Trial name
- NCT07750379
- Testing
- PPI, vitamin D, feeding instruction
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Minia University
Chronic Kidney Disease, Pneumonia
Proton Pump Inhibitor Use is Associated With High Risk of Pneumonia in Chronic Kidney Disease Patients
Chronic kidney disease is a severe medical problem in Taiwan public health issue, which the highest incidence and prevalence rate in the world.Proton pump inhibitors may increase the risk of pneumonia appearance, which were…
- Trial name
- NCT01588886
- Volunteers
- 9,000 people
- Sponsor
- Far Eastern Memorial Hospital
Pediatric Obesity, NAFLD
Effect of Obesity on Proton Pump Inhibitors
This longitudinal study tests the hypothesis that obesity affects drug pharmacology of acid suppression medications in children.
- Conditions
- Pediatric Obesity, NAFLD, GERD
- Trial name
- LiverLabPPI (NCT04248335)
- Testing
- Lansoprazole, Pantoprazole, Midazolam
- Where
- United States
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- Children's Mercy Hospital Kansas City
Gastroesophageal Reflux
Randomized Trial for Pharmacogenomics-based Proton Pump Inhibitor Therapy in Children
Proton pump inhibitors are administered to children as off-label use in Japan. The purpose of this study is to evaluate the effects of CYP2C19 genotypes on pharmacokinetic /pharmacodynamic profiles of PPI in children.
- Trial name
- NCT00299845
- Testing
- Lansoprazole
- Where
- Japan
- Sponsor
- Osaka University
Erosive Reflux Disease, Non-erosive Reflux Disease
Predictors of Proton Pump Inhibitor Response in Gastroesophageal Reflux Disease Patients
Proton pump inhibitor (PPI) is widely used in patients with gastroesophageal reflux disease (GERD), however, some patients fail to respond to PPI therapy.
- Conditions
- Erosive Reflux Disease, Non-erosive Reflux Disease, Functional Heartburn
- Trial name
- NCT01797939
- Where
- South Korea
- Volunteers
- 197 people
- Sponsor
- Seoul National University Bundang Hospital
Otitis Media With Effusion
A Clinical Trial of Proton Pump Inhibitors to Treat Children With Chronic Otitis Media With Effusion
This study is being done to see if reflux of stomach fluid might be a cause of chronic fluid in the ears. Our hypothesis is that treatment with an anti-reflux medication (lansoprazole) will increase the rate of resolution of…
- Trial name
- NCT00546117
- Testing
- lansoprazole
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Washington University School of Medicine
Gastroesophageal Reflux Disease, Gastritis
Analysis of Biopsies From the Upper Gastrointestinal Tract
Multicenter study to correlate histological findings in the upper gastrointestinal tract with endoscopic and clinical data.
- Trial name
- histoGERD (NCT01576289)
- Testing
- Histological analysis
- Where
- Austria
- Volunteers
- 600 people
- Sponsor
- Medical University of Graz
Upper Gastrointestinal Bleeding
Oral vs Intravenous and Proton Pump Inhibitor (PPI）for Peptic Ulcer Bleeding (PUB)
A bleeding peptic ulcer remains a serious medical problem with significant morbidity and mortality. Endoscopic therapy significantly reduces further bleeding, surgery, and mortality in patients with bleeding peptic ulcers and is…
- Trial name
- NCT01123031
- Testing
- lansoprazole, esomeprazole
- Sponsor
- Changhua Christian Hospital
Marginal Ulcer
OPEN Versus InTact Capsule Proton Pump Inhibitors for the Treatment of Marginal Ulcers
The goal of this clinical trial is to identify the most effective way to take acid-blocking medications to treat stomach ulcers in patients who have undergone gastric bypass surgery.
- Trial name
- OPEN-IT (NCT05799105)
- Testing
- Omeprazole 40 milligrams
- Where
- United States
- Volunteers
- 122 people
- Sponsor
- Stephen Firkins
Death, Sudden, Cardiac
An Observational Study to Assess the Risk of Out-of-Hospital Sudden Cardiac Death in Users of Domperidone, Users of Proton Pump Inhibitors, and Users of Metoclopramide
The purpose of this observational study is to assess the risk of out-of-hospital Sudden Cardiac (heart) Death (SCD) associated with current use of domperidone compared to current use of a Proton Pump Inhibitor (PPI), current use…
- Trial name
- NCT01907633
- Testing
- No intervention
- Volunteers
- 15,000 people
- Sponsor
- Janssen Research & Development, LLC
Prescription Pattern
Academic Detailing About Proton Pump Inhibitors
General practices in the Capital Region of Denmark are offered a short educational visit and are randomized to either proton pump inhibitor (intervention) or another topic (control).
- Trial name
- BRIEF-PI (NCT05443789)
- Testing
- Proton pump inhibitor education, Other education
- Where
- Denmark
- Volunteers
- 360 people, healthy volunteers welcome
- Sponsor
- Jón Þór Trærup Andersen
Chest Pain Rule Out Myocardial Infarction
PPI's and SSRI's Therapy for the Management of NCCP
Non cardiac chest pain (NCCP) is defined as recurring, angina-like, retrosternal chest pain of non cardiac origin. Annual prevalence of NCCP in the general population of the western world ranges from 25-35%.
- Trial name
- NCCP (NCT02825342)
- Testing
- Citalopram
- Where
- Greece
- Volunteers
- 60 people
- Sponsor
- Evangelismos Hospital
Hematopoietic Stem Cell Transplantation (HSCT), aGVHD
GMPA Versus PPI for Gastric Protection and aGVHD Risk
The goal of this clinical trial is to observe whether different gastric protection strategies affect the incidence of acute graft-versus-host disease (aGVHD) in patients undergoing allogeneic hematopoietic stem cell…
- Conditions
- Hematopoietic Stem Cell Transplantation (HSCT), aGVHD, Infection, Mortality
- Trial name
- NCT07791849
- Testing
- Teprenone, Esomeprazole
- Where
- China
- Volunteers
- 198 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
Gastroesophageal Reflux
The Gastrointestinal Microbiome of Infants With GERD and PPI Therapy: a Pilot Study
Proton Pump Inhibitors (PPI) are standard in the therapy of pediatric GERD. In the past it has been hypothesized, that either direct inhibition of bacterial ATPase or elevation of the pH may lead to changes in the intestinal…
- Trial name
- NCT02359604
- Testing
- PPI therapy, Stool sample
- Where
- Austria
- Volunteers
- 12 people
- Sponsor
- Medical University of Graz
Osteopenia, Prematurity
Proton Pump Inhibitor Therapy and Bone Density in Premature Infants
Previous research studies have shown that there may be a connection between proton pump inhibitor therapies and hip fracture in adults(1).
- Trial name
- PPI (NCT00888017)
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Utah
Gastroesophageal Reflux Disease (GERD)
Symptom Improvements in Gastroesophageal Reflux Disease (GERD) Patients
The purpose of this study is to estimate the effect of AZD3355 as an add-on treatment to a Proton Pump Inhibitor (PPI) on Gastroesophageal reflux disease (GERD) symptoms in patients with an incomplete response to PPI treatment.
- Trial name
- NCT00394472
- Testing
- AZD3355
- Where
- 38 sites in Australia, Belgium and 6 more
- Volunteers
- 244 people
- Sponsor
- AstraZeneca
Signs and Symptoms
Effect of Proton Pump Inhibitors on Palpitations
Palpitation is a common complaint. Patients frequently feel this symptom despite having normal rhythm during symptoms. I have seen many patients who improve significantly on treatment with proton pump inhibitors (PPI).
- Trial name
- NCT02826408
- Testing
- Rabeprazole sodium, Pacebo
- Where
- Jordan
- Volunteers
- 30 people
- Sponsor
- Jordan Collaborating Cardiology Group
Food Allergy
Integrated Approaches to Food Allergen and Allergy Risk Management
Patients with history of a food allergy to hazelnut, walnut or celeriac will undergo food provocation with a dose of the allergenic food to which 5% of the respective food allergic population (ED05) has been calculated to respond…
- Trial name
- iFAAM (NCT02295397)
- Testing
- food
- Where
- Switzerland
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- University of Zurich
Systemic Sclerosis (SSc), GERD (Gastroesophageal Reflux Disease)
PPI Refractory - GERD Mechanisms in Systemic Sclerosis
The goal of this observational study is to learn about the mechanisms of gastroesophageal reflux disease (GERD) in patients with systemic sclerosis (SSc) who continue to experience reflux symptoms despite treatment with proton…
- Trial name
- NCT07022912
- Testing
- educational healthcare intervention, Objective assessment of GI motility, Evaluation of GERD severity
- Volunteers
- 147 people
- Sponsor
- Hospital Universitari Vall d'Hebron Research Institute
Gastroesophageal Reflux
Safety and Efficacy of Rabeprazole in Infants With Gastroesophageal Erosive Reflux Disease (GERD)
The purpose of this study is to assess the effectiveness and safety of rabeprazole sodium, an inhibitor of gastric acid secretion of the protein pump inhibitor (PPI) class, compared with placebo in the treatment of…
- Trial name
- NCT00992589
- Testing
- Rabeprazole sodium 5 mg, Rabeprazole sodium 10 mg
- Where
- 81 sites in United States, Australia and 8 more
- Volunteers
- 344 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.